| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 530396000 | Lectins, e.g., concanavalin, hemagglutinin, etc. | 9 |
| 20090275740 | NOVEL COLLECTIN - Provided are isolated collectin (CL-L2s) genes including a base sequence set out in SEQ ID NO: 1, 3, 5, 7, 9, 12, 36, 38 or 40 relating to a novel collectin which are expected to exhibit an antibacterial activity, an antiviral activity and the like particularly in a human body; and isolated collectin proteins including an amino acid sequence set out in SEQ ID NO: 2, 4, 6, 8, 10, 13, 37, 39 or 41 and derivatives and fragments thereof. | 11-05-2009 |
| 20120277413 | Dendritic Cell Marker BDCA-2 Protein Sequence - The invention provides antigen-binding fragments specific for dendritic cells and effective in treatment and/or diagnosing a variety of disorders. Methods of use are also provided as are methods for screening for additional such antigen-binding fragments and the products obtained thereby. | 11-01-2012 |
| 20130018178 | METHOD FOR THE PURIFICATION OF HBHAAANM Laronze; AurelieAACI GrenobleAACO FRAAGP Laronze; Aurelie Grenoble FRAANM Mouz; NicolasAACI Saint Paul De VarcesAACO FRAAGP Mouz; Nicolas Saint Paul De Varces FRAANM Pech; JoanaAACI Saint EgreveAACO FRAAGP Pech; Joana Saint Egreve FR - The present invention concerns a new method for the purification of Heparin Binding Hemagglutinin (HBHA) robust and reproducible at an industrial scale. The purification is made from HBHA-producing microorganisms extracted in presence of a detergent, a solvent or a chaotropic agent, followed by a first elution on ion exchange resins. In a preferred embodiment, the elution on ion exchange resins is followed by a second chromatography on mixed mode sorbents. | 01-17-2013 |
| 20130085267 | Stabilization of Therapeutic Agents to Facilitate Administration - The present invention provides for a carrier complex for administration of therapeutic agents. In one aspect, an isolated | 04-04-2013 |
| 20130150565 | NOVEL COLLECTIN - Provided are isolated collectin (CL-L2s) genes including a base sequence set out in SEQ ID NO: 1, 3, 5, 7, 9, 12, 36, 38 or 40 relating to a novel collectin which are expected to exhibit an antibacterial activity, an antiviral activity and the like particularly in a human body; and isolated collectin proteins including an amino acid sequence set out in SEQ ID NO: 2, 4, 6, 8, 10, 13, 37, 39 or 41 and derivatives and fragments thereof. | 06-13-2013 |
| 20140235836 | Immunologic Constructs and Methods - The present invention relates to improved vaccines and the design and making of such vaccines that enhance immunogenicity of the vaccine and/or reduce reactogenicity to the vaccine when administered. In particular the vaccines and immunogenic compositions of the present invention relate to flagellin-antigen fusion proteins in which the spatial orientation of the flagellin to antigen and the charge distribution of the antigen is optimized to enhance immunogenicity and/or reduce reactogenicity and/or improve folding of the protein. | 08-21-2014 |
| 20140296494 | PROTEIN EXPRESSION IN PLANTS - The present invention relates to protein expression in plants, particularly the large-scale production of recombinant polypeptides in whole | 10-02-2014 |
| 20140357845 | INFLUENZA VIRUS VACCINES AND USES THEREOF - The present disclosure provides influenza hemagglutinin stem domain polypeptides comprising (a) an influenza hemagglutinin HA1 domain that comprises an HA1 N-terminal stem segment, covalently linked by a linking sequence of 0-50 amino acid residues to an HA1 C-terminal stem segment, and (b) an influenza hemagglutinin HA2 domain, wherein on or more amino acids in the HA2 domain have been mutated. Also provided are nucleic acids encoding the polypeptides, compositions comprising the polypeptides and/or nucleic acid molecules, as well as methods of their use, in particular in the detection, prevention and/or treatment of influenza. | 12-04-2014 |
| 20150307574 | MODIFIED GALECTIN-9 PROTEIN - The present invention provides galectin-9 variant having substantially the same bioactivity as in wild-type galectin-9 and being superior in protease stability, solubility, and yield. The galectin-9 variant according to the present invention is a protein including the following NCRD and the following CCRD composed of an N-terminal region and a C-terminal region. The C terminus of the NCRD and the N terminus of the CCRD are directly or indirectly bound to each other. The NCRD is (N1) a peptide composed of an amino acid sequence represented by SEQ ID NO: 1. The N-terminal region of the CCRD is (C-N1) a peptide composed of an amino acid sequence obtained by deletion of 1 to 17 amino acids in an amino acid sequence represented by SEQ ID NO: 3. The C-terminal region is (C-C1) a peptide composed of an amino acid sequence represented by SEQ ID NO: 5. | 10-29-2015 |
